Scott Wadler

10.7k citations
195 papers · 8.6k · 2 hit papers · h-index 45

Impact in

  • Oncology top 0.5%
    • Colorectal Cancer Treatments and Studies
    • Cancer Treatment and Pharmacology
    • Ovarian cancer diagnosis and treatment

Papers in

    • Colorectal Cancer Treatments and Studies 48
    • Cancer Treatment and Pharmacology 21
    • Cancer therapeutics and mechanisms 16

Scott Wadler

192 papers receiving 8.2k citations

Scott Wadler's Hit Papers

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group 2001 · 847 citations
8470+9+19Years since publication250500750

Peers

Scott Wadler
Comparison fields: 5 of 133
  • Oncology 3.9k
  • Reproductive Medicine 884
  • Hepatology 533
  • Otorhinolaryngology 287
  • Obstetrics and Gynecology 361
Replace G. Stoter with:
G. Stoter Netherlands
Peter Harper United Kingdom
Lisa Wang Canada
Massimo Di Maïo Italy
Paul Sabbatini United States
Francesco Perrone Italy
Howard S. Höchster United States
Jourik A. Gietema Netherlands
Geoffrey R. Weiss United States
Siqing Fu United States
Scott Wadler relative to G. Stoter Netherlands G. Stoter's profile →
Citations per field
00.5×4.5×
G. Stoter · 1×
Citations per year

Countries citing papers authored by Scott Wadler

Since Specialization
Citations

This map shows the geographic impact of Scott Wadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Wadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Wadler more than expected).

Fields of papers citing papers by Scott Wadler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Wadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Wadler. The network helps show where Scott Wadler may publish in the future.

Co-authors

The 25 scholars most cited alongside Scott Wadler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Scott Wadler Line = papers co-authored together Scott Wadler links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 195 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
Hit paper breakdown →
2001847
2
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Hit paper breakdown →
1997513
3 2004461
4 2007351
5 2001347
6
Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
1990303
7 1989279
8
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
1998211
9 2000159
10 2005148
11
A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
2001130
12 1991127
13 1998126
14 2004120
15
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
2003120
16 2007120
17
Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.
1990117
18 1992114
19 2003113
20
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.
1990109

About Scott Wadler

Scott Wadler is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine, having authored 195 papers that have together received 8.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (48 papers), Cancer Treatment and Pharmacology (21 papers), Ovarian cancer diagnosis and treatment (20 papers), Cancer therapeutics and mechanisms (16 papers), Lung Cancer Treatments and Mutations (15 papers), Gastric Cancer Management and Outcomes (14 papers), Genetic factors in colorectal cancer (14 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). The work is most often cited by research in Oncology (3.9k citations), Reproductive Medicine (884 citations), Hepatology (533 citations), Otorhinolaryngology (287 citations) and Obstetrics and Gynecology (361 citations). Scott Wadler has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Edward L. Schwartz, Della Makower, David S. Alberts, Maurie Markman, Linda F. Carson, Brian N. Bundy, Jeffrey M. Fowler, Joshua Z. Sickel, Al B. Benson and Jonathan J. Beitler. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Cancer, Investigational New Drugs and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact